Cardiovascular effects of canrenone in patients with preascitic cirrhosis

Giorgio La Villa1, Giuseppe Barletta, Roberto Giulio Romanelli

  • 1Department of Internal Medicine, University of Florence School of Medicine, Azienda Ospedaliera Careggi, Florence, Italy. g.lavilla@dmi.unifi.it

Insights

Canrenone, an aldosterone antagonist, normalized abnormal cardiac responses to standing in patients with cirrhosis and portal hypertension. This suggests canrenone improves myocardial function and cardiac compensation in these patients.

Area of Science:

  • Cardiology
  • Hepatology
  • Pharmacology

Background:

  • Patients with cirrhosis and portal hypertension exhibit abnormal hemodynamic responses to standing, including reduced cardiac index (CI) and impaired left ventricular (LV) function.
  • This dysfunction is attributed to an inability to adequately increase LV ejection fraction (EF) and stroke volume to compensate for reduced preload upon standing.

Purpose of the Study:

  • To investigate the effect of canrenone, an aldosterone antagonist, on cardiac dysfunction and hemodynamic responses to postural changes in patients with preascitic cirrhosis and portal hypertension.

Main Methods:

  • Eight patients with preascitic cirrhosis underwent echocardiography and hemodynamic assessments in supine and standing positions.
  • Measurements included plasma volume, urinary sodium excretion, plasma renin activity (PRA), aldosterone (PAC), and norepinephrine (PNE) at baseline and after 1 month of canrenone treatment with varying sodium intake (40 or 150 mmol/d).

Main Results:

  • At baseline, patients showed a significant reduction in CI and LVEF upon standing.
  • After canrenone treatment, the detrimental decrease in LVEF and CI during standing was abolished.
  • Canrenone also led to increased PRA and PNE, and a decrease in plasma volume, particularly with a low-sodium diet.

Conclusions:

  • Canrenone effectively normalizes the cardiac response to the postural challenge in patients with preascitic cirrhosis and portal hypertension.
  • Aldosterone antagonism with canrenone may improve myocardial function and hemodynamic stability in this patient population.

Related Concept Videos

Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Ascites01:19

Ascites

DefinitionAscites is the buildup of fluid inside the peritoneal cavity. It occurs when fluid moves out of the vascular system faster than the peritoneal lymphatics can remove it. This fluid shift is most commonly seen in liver cirrhosis but can also appear in several other systemic disorders.EtiologyCirrhosis remains the leading cause of ascites. Other conditions that can contribute include:Heart failureConstrictive pericarditisAbdominal cancersNephrotic syndromeSevere protein–calorie...
Exercise and Cardiovascular Response01:20

Exercise and Cardiovascular Response

Exercise significantly impacts cardiovascular response, which is crucial for understanding patient health and designing effective treatment plans.
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...